Curbstone Financial Management Corp lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 30,442 shares of the company’s stock after selling 250 shares during the quarter. Johnson & Johnson comprises approximately 1.2% of Curbstone Financial Management Corp’s holdings, making the stock its 19th largest position. Curbstone Financial Management Corp’s holdings in Johnson & Johnson were worth $3,929,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Selective Wealth Management acquired a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $105,000. Fusion Family Wealth LLC increased its holdings in Johnson & Johnson by 621.4% in the 2nd quarter. Fusion Family Wealth LLC now owns 1,010 shares of the company’s stock valued at $123,000 after purchasing an additional 870 shares during the last quarter. Ifrah Financial Services Inc. acquired a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $203,000. Exane Asset Management acquired a new stake in Johnson & Johnson in the 2nd quarter valued at approximately $206,000. Finally, Peak Capital Management LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at approximately $207,000. Institutional investors and hedge funds own 66.43% of the company’s stock.
JNJ has been the subject of several research reports. ValuEngine upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Thursday, December 13th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $164.00 target price for the company in a report on Wednesday, December 12th. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating for the company in a report on Wednesday, January 2nd. Barclays reiterated an “equal weight” rating and issued a $135.00 target price (down previously from $137.00) on shares of Johnson & Johnson in a report on Wednesday, January 23rd. Finally, Citigroup dropped their price target on shares of Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating for the company in a research note on Wednesday, January 2nd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company. Johnson & Johnson has an average rating of “Hold” and an average price target of $142.81.
NYSE:JNJ opened at $136.91 on Friday. The firm has a market capitalization of $370.51 billion, a price-to-earnings ratio of 16.74, a price-to-earnings-growth ratio of 2.12 and a beta of 0.68. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.47 and a quick ratio of 1.20. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.99.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, January 22nd. The company reported $1.97 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.95 by $0.02. The business had revenue of $20.39 billion during the quarter, compared to the consensus estimate of $20.27 billion. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The company’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.74 earnings per share. On average, sell-side analysts anticipate that Johnson & Johnson will post 8.57 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 12th. Shareholders of record on Tuesday, February 26th were paid a $0.90 dividend. The ex-dividend date was Monday, February 25th. This represents a $3.60 annualized dividend and a dividend yield of 2.63%. Johnson & Johnson’s dividend payout ratio (DPR) is 44.01%.
Johnson & Johnson declared that its board has approved a stock buyback program on Monday, December 17th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the company to reacquire up to 1.5% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.
COPYRIGHT VIOLATION NOTICE: This story was reported by Enterprise Leader and is owned by of Enterprise Leader. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://theenterpriseleader.com/2019/03/24/johnson-johnson-jnj-stake-lessened-by-curbstone-financial-management-corp.html.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: What causes a recession?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.